Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Hepatitis
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…
Six months of treatment with Kezar Life Sciences‘ candidate zetomipzomib led to biochemical disease remission for adults with treatment-resistant autoimmune hepatitis, enabling them…
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Researchers have discovered a key mechanism that allows the hepatitis B virus (HBV) to infect and persist in liver cells, in a new study…
A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…
Recent Posts
- Fearing liver cancer when you’re living with fatty liver disease
- Urine tests unreliable for pediatric cholestasis screening: Study
- Trial of WVE-007 for obesity aims to inform decisions about drug for MASH
- I’m grateful to make connections with the rare disease community
- Most babies with biliary atresia test positive for rotavirus antibodies